In its first-quarter 2026 investor letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Ionis Pharmaceuticals ...
The FDA has approved Tryngolza (olezarsen) to reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (TG ≥500mg/dL).
President Donald Trump has promised to make U.S. prescription drug prices the cheapest in the world, but a closely watched ...
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer's disease, including clinical, biomarker and safety results for Biogen's investigational tau-targeting ASO, following topline ...
Earlier this week, Ionis Pharmaceuticals reported that the FDA approved Tryngolza (olezarsen) to reduce triglycerides and the ...
Ionis Pharmaceuticals draws attention after a rare-disease therapy license agreement, keeping its RNA-targeted medicine ...
U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty ...
Earlier this year, Ionis' CEO Brett Monia said that Tryngolza (olezarsen) would become the company's first fully owned ...
Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction June 24, ...
Zacks Investment Research on MSN
FDA expands IONS' Tryngolza label to treat severe hypertriglyceridemia
Ionis Pharmaceuticals IONS announced that the FDA has approved its wholly owned drug, Tryngolza (olezarsen), for a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results